Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research focused on Apatinib and Oxaliplatin, with related work in Epigenetics, Micelle, Psychosocial. Notable publications include 'First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study', 'Degraders in epigenetic therapy: PROTACs and beyond', and 'Cross‐Linkable Polyion Complex Micelles from Polypept(o)ide‐Based ABC‐Triblock Copolymers for siRNA Delivery'.
CACA clinical guideline of holistic psychosocial care for cancer patients
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Degraders in epigenetic therapy: PROTACs and beyond
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.
The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China
Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
Cross‐Linkable Polyion Complex Micelles from Polypept(o)ide‐Based ABC‐Triblock Copolymers for siRNA Delivery